Form 4: Vaxart SVP, General Counsel Edward Berg Reports Share Transaction

Edward Berg, SVP and General Counsel of Vaxart, Inc., reports the withholding of 8,050 common stock shares to cover income tax obligations related to vested RSUs.

Summary

• On March 18, 2025, Edward Berg, SVP and General Counsel of Vaxart, Inc., had 8,050 common stock shares withheld by the issuer to cover income tax obligations related to the net settlement of vested Restricted Stock Units (RSUs).
• The transaction occurred at a price of $0.5702 per share.
• Following the transaction, Berg directly owns 288,123 shares of Vaxart common stock, which includes 70,781 shares acquired under the company's 2022 Employee Stock Purchase Plan.
• Berg has granted power of attorney to Steven Lo, Phillip Lee, and Faith L. Charles to execute and file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a routine disclosure related to executive compensation and tax obligations, common for publicly traded companies. It provides transparency into the stock ownership of key personnel.

Comparison to Industry Standards

• Executive compensation practices, including the use of RSUs and ESPPs, are standard across the biotechnology industry.
• Companies like Moderna, BioNTech, and Novavax also utilize similar compensation structures for their executives.
• The reporting of share transactions via Form 4 is a standard regulatory requirement for insiders of publicly traded companies.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it involves a small number of shares withheld for tax purposes.
• The disclosure provides transparency to stakeholders regarding executive stock ownership.

Key Dates

Keywords

Vaxart, Edward Berg, Form 4, SEC, Beneficial Ownership, Share Transaction, RSUs, Employee Stock Purchase Plan, Power of Attorney